1. Experimental HIV Vaccine Research 

The UCLA CARE center is conducting a research study of an experimental vaccine against HIV:

This is not an approval vaccine and not to be used as protection against HIV or other sexually transmitted diseases.

subjects must be HIV negative and at low risk for HIV and be between age of 18 and 50. 

Participants will receive either an injection of the experimental vaccine or placebo 4 times over one year period and will be followed over a period of 25 months.For more information and participants, please call 310-206-6414

UCLA M-IRB# 00-12-023-01A

2. Dr. Steven Dubinett, director of the UCLA Lung Cancer Research Program at the Jonsson Cancer Center and professor of medicine in the Division of Pulmonary and Critical Care Medicine, are investigating Celebrex's potential to prevent lung cancer( cancer-related research on the anti-inflammatory drug Celebrex). 

3. Dr. Jenny Mao, lead investigator for the studies. Mao also is a researcher at UCLA's Jonsson Cancer Center, an assistant professor, director of the Life-Lung Bronchoscopy Program and director of the Comprehensive Second-Lung Cancer Surveillance and Chemoprevention Program at the UCLA School of Medicine.

4. Announced a need for participants in a study on estrogen's effect on memory, mood and brain function in perimenopausal women. Melinda Morgan, a post-doctoral fellow in adult psychiatry at the UCLA Neuropsychiatric Institute, is conducting the study.

5.The National Lung Screening Trial

Enrolling healthy men and women in research to detect lung cancer.

WHAT’S THE PURPOSE OF THIS STUDY?
The purpose of this study is to compare two ways of detecting lung cancer: standard chest X-ray and helical computed tomography (CT) scan. Both chest x-rays and CT scans are used in an effort to find lung cancer early. So far, neither chest x-rays nor CT scans has been shown to reduce a person’s chance of dying from lung cancer. This study will attempt to show which test is better at reducing deaths from this disease.

WHO CAN PARTICIPATE?
· Healthy men and women aged 55-75 years
· Current or former smokers who have smoked heavily, or have smoked for many years
· People who have no known cancers or treatment for cancer within the past 5 years (exclude non-melanoma skin cancer and in-situ cancers)
· Not currently enrolled in any other screening or cancer prevention trial

WHY SHOULD YOU PARTICIPATE?
NLST offers participants:
· The possibility of detecting a small lung cancer that may still be curable
· The chance to contribute to medical research and to help others and future generations
· Referrals to smoking cessation resources if you want to quit

WHAT IS INVOLVED IF YOU QUALIFY TO PARTICIPATE?
· Complete detailed questionnaires
· Perform a Pulmonary Function Test
· Give samples of blood, urine, and sputum (phlegm)
· Being assigned by chance to receive a CT scan or CXR once a year for three years
· Provide health history information every six months for up to 8 years

HOW DO YOU FIND OUT MORE ABOUT THE STUDY?

This is a multi-center clinical trial sponsored jointly by the American College of Radiology Imaging Network (ACRIN) and the National Cancer Institute (NCI). The study is being conducted at UCLA by Dr. Jonathan Goldin in the Department of Radiology. For more information, contact the UCLA Study Coordinator @ (310) 206-4624 or NLST@mednet.ucla.edu <mailto:NLST@mednet.ucla.edu>.

Your participation is completely voluntary. You may choose to withdraw from the study at any time.

www.chsir.com is not involved in this study.